Nora Volkow links changing scientific views on psychedelics to emerging evidence, highlighting NIH caution, therapeutic promise, and the need for rigorous research

Nora Volkow centers scientific evidence as the basis for changing views on psychedelics, while stressing that enthusiasm should be matched by rigorous research, safety oversight, and realistic expectations. Her stance reflects a more open posture inside mainstream US science institutions, even as federal caution around approval pathways and public messaging remains strong. Clinical interest has grown around psychedelic-assisted treatment for conditions such as depression, PTSD, and addiction, with psilocybin and MDMA often driving the discussion and ketamine providing a partial precedent. The central tension lies between promising early results and the need for larger, better controlled trials that can clarify efficacy, risk, durability, and patient selection. That shift matters because NIH leadership strongly influences research legitimacy, funding priorities, and how psychedelic science is received across medicine and policy. Evidence-based openness from a figure like Volkow signals that psychedelic research is moving further into the scientific mainstream without removing the demand for high standards.